Clinical Trial Update: A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring hepatic arterial infusion combined with apatinib and camrelizumab for C-staged hepatocellular carcinoma (BCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: C-staged Hepatocellular Carcinoma in BCLC Classification | Phase 2 | Status: UNKNOWN